Background/Aims: To examine the prevalence and clinical characteristics of apparent treatment-resistant hypertension among ambulatory hypertensive patients. Methods: We enrolled adult ambulatory hypertensive patients at 13 well-qualified general hospitals in Korea from January to June 2012. Apparent resistant hypertension was defined as an elevated blood pressure > 140/90 mmHg with the use of three antihypertensive agents, including diuretics, or ≥ 4 antihypertensives, regardless of the blood pressure. Controlled hypertension was defined as a blood pressure within the target using three antihypertensives, including diuretics. Results: Among 16,915 hypertensive patients, 1,172 (6.9%) had controlled hypertension, and 1,514 (8.9%) had apparent treatment-resistant hypertension. Patients with apparent treatment-resistant hypertension had an earlier onset of hypertension (56.8 years vs. 58.8 years, p = 0.007) and higher body mass index (26.3 kg/m2 vs. 24.9 kg/m2, p < 0.001) than those with controlled hypertension. Drug compliance did not differ between groups. In the multivariable analysis, earlier onset of hypertension (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.97 to 0.99; p < 0.001) and the presence of comorbidities (OR, 2.06; 95% CI, 1.27 to 3.35; p < 0.001), such as diabetes mellitus, ischemic heart disease, heart failure, and chronic kidney disease, were independent predictors. Among the patients with apparent treatment-resistant hypertension, only 5.2% were receiving ≥ 2 antihypertensives at maximally tolerated doses. Conclusions Apparent treatment-resistant hypertension prevalence is 8.9% among ambulatory hypertensive patients in Korea. An earlier onset of hypertension and the presence of comorbidities are independent predictors. Optimization of medical treatment may reduce the rate of apparent treatment-resistant hypertension.

Background/Aims: To examine the prevalence and clinical characteristics of apparent treatment-resistant hypertension among ambulatory hypertensive patients. Methods: We enrolled adult ambulatory hypertensive patients at 13 well-qualified general hospitals in Korea from January to June 2012. Apparent resistant hypertension was defined as an elevated blood pressure > 140/90 mmHg with the use of three antihypertensive agents, including diuretics, or ≥ 4 antihypertensives, regardless of the blood pressure. Controlled hypertension was defined as a blood pressure within the target using three antihypertensives, including diuretics. Results: Among 16,915 hypertensive patients, 1,172 (6.9%) had controlled hypertension, and 1,514 (8.9%) had apparent treatment-resistant hypertension. Patients with apparent treatment-resistant hypertension had an earlier onset of hypertension (56.8 years vs. 58.8 years, p = 0.007) and higher body mass index (26.3 kg/m2 vs. 24.9 kg/m2, p < 0.001) than those with controlled hypertension. Drug compliance did not differ between groups. In the multivariable analysis, earlier onset of hypertension (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.97 to 0.99; p < 0.001) and the presence of comorbidities (OR, 2.06; 95% CI, 1.27 to 3.35; p < 0.001), such as diabetes mellitus, ischemic heart disease, heart failure, and chronic kidney disease, were independent predictors. Among the patients with apparent treatment-resistant hypertension, only 5.2% were receiving ≥ 2 antihypertensives at maximally tolerated doses. Conclusions Apparent treatment-resistant hypertension prevalence is 8.9% among ambulatory hypertensive patients in Korea. An earlier onset of hypertension and the presence of comorbidities are independent predictors. Optimization of medical treatment may reduce the rate of apparent treatment-resistant hypertension.

No abstract available.
Bone Marrow/pathology ; Chromosomes, Human, Pair 12 ; Chromosomes, Human, Pair 9 ; Core Binding Factor Alpha 2 Subunit/*genetics ; DNA/metabolism ; Gene Rearrangement ; Humans ; In Situ Hybridization, Fluorescence ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*genetics ; Male ; Middle Aged ; Oncogene Proteins, Fusion/*genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Translocation, Genetic

Human epididymis protein 4 (HE4) has been suggested as a useful new biomarker of lung cancer; however, few relevant large-scale studies have been published. In this study, we evaluated the utility of serum HE4 for lung cancer detection. HE4 levels were measured in serum samples from 100 lung cancer patients, 57 patients with benign lung diseases, and 274 healthy controls by using a chemiluminescent immunoassay, and variations in HE4 levels were analyzed by clinical status such as lung cancer, benign lung disease, and healthy condition, Tumor, Lymph Nodes, Metastasis (TNM) stage, tumor score, and histological cancer type. Lung cancer patients had significantly higher serum HE4 levels than patients with benign lung diseases and healthy controls (P<0.0001). The area under the ROC curve for HE4 was 0.84 (95% confidence interval, 0.78–0.89; P<0.0001) between lung cancer patients and healthy controls. Serum HE4 levels were significantly higher in patients with advanced disease (according to TNM stage) than in healthy controls (P<0.0001). HE4 levels were significantly elevated in patients with tumors of all types, those of different histological subgroups, and those with the smallest tumors (P=0.002). This report supports the potential of serum HE4 as an ancillary diagnostic marker for lung cancer detection.
Biomarkers, Tumor ; Epididymal Secretory Proteins ; Humans* ; Immunoassay ; Lung Diseases ; Lung Neoplasms* ; Lung* ; Lymph Nodes ; Male ; Neoplasm Metastasis ; ROC Curve

BACKGROUND: Prompt and accurate urine chemistry analysis is important to provide information for diagnosis and therapy. In this study, we evaluated the overall performance and utility of an automated chemistry analyser for urine chemistry testing in accordance with Clinical and Laboratory Standards Institute guidelines. METHODS: From January 2015 to March 2015, we evaluated the precision, linearity, limits of detection, carryover, and turnaround times after automation of nine items: total protein, albumin, glucose, blood urea nitrogen, total calcium, magnesium, inorganic phosphate, creatinine, and uric acid. A Hitachi 7600-110 instrument (Hitachi Ltd., Japan) and Hitachi ID Privileged Access Manager (Hitachi Ltd.) were used for automated chemistry analysis and sample preparation, respectively. RESULTS: Regarding precision, the coefficient of variation was 3.9% to 1.6% for high levels and 3.3% to 24.1% for low levels. The linearity and coefficients of determination of all the test items were acceptable. Performance comparison revealed that the two systems were comparable, as evidenced by correlation coefficients >0.975 for most items; moreover, carryover of all items was <1%. The mean turnaround time was 59 minutes. CONCLUSIONS: Urine chemistry testing can be performed with acceptable precision, linearity, and performance by using the Hitachi 7600-110 automated chemistry analyser. The sample preparation system reduces turnaround time, which enhances the clinical utility of urine chemistry testing.
Automation ; Blood Glucose ; Calcium ; Chemistry* ; Creatinine ; Diagnosis ; Limit of Detection ; Magnesium ; Nitrogen ; Urea ; Uric Acid

Mycobacterium neoaurum is rapidly growing mycobacteria that can cause human infections. It commonly causes bloodstream infections in immunocompromised hosts, and unlike other mycobacteria species, it rarely causes pulmonary infections. We confirmed the first pulmonary infection case in Korea caused by M. neoaurum using full-length 16S rRNA gene sequencing.
Adult ; Female ; Humans ; Lung Diseases/*diagnosis/microbiology ; Mycobacterium/genetics/*isolation & purification ; Mycobacterium Infections/*diagnosis/microbiology ; Nontuberculous Mycobacteria/genetics/isolation & purification ; RNA, Ribosomal, 16S/genetics ; Republic of Korea ; Sequence Analysis, RNA

BACKGROUND: Majority of clinical laboratories disseminate laboratory test information through guidebooks or handouts. However, these methods cannot instantly confer information, for example, when a novel laboratory test is introduced, or a change is made to a test request procedure or type of specimen involved. To overcome these limitations, we developed a mobile web application that is a laboratory test information repository, initially for use in Korea. METHODS: We established a laboratory master database of searchable laboratory test information using a web-based framework. Information pertaining to clinical test indications, interpretation of test results, and related laboratory tests was revised; test request guidelines were also updated. Information concerning tests that are occasionally subject to change and newly introduced tests was updated promptly. RESULTS: Our mobile web-based application uses the domain name www.schlab.org and can also be accessed via a desktop browser. The information for each test includes basic details such as specimen type, container, turnaround time, and so on and an introduction in addition to a more detailed explanation of associated tests and usage recommendations. The number of monthly visitors to the site was 529 (649 page views), with visitors using the mobile web for 31 seconds per visit. CONCLUSIONS: We developed a mobile web application that provides information on laboratory tests. We improved on the existing method of transmitting such information (i.e., a laboratory request guidebook) by offering a system that provides updated test information and increased accessibility. Our method is expected to reduce instances of inaccurate or unnecessary test orders, improper specimen collection, delayed specimen arrival, and inappropriate treatment.
Clinical Laboratory Services ; Information Services ; Korea ; Mobile Applications ; Specimen Handling ; Smartphone

No abstract available.
Adult ; Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; Clindamycin/therapeutic use ; Female ; Humans ; Malaria, Vivax/*diagnosis/drug therapy/parasitology ; Neutrophils/*parasitology ; Plasmodium vivax/growth & development/*isolation & purification ; Pregnancy ; Quinine/therapeutic use ; Trophozoites/cytology

The lymphoproliferative disease multiple myeloma and the myeloproliferative disease polycythemia vera have different pathogenic mechanisms and different natural courses. Thus, the concomitant development of these two diseases in the same individual is rare. In most previously reported cases of both diseases, one disease was assumed to be a secondary malignancy caused by chemotherapy for the other primary disease. Our case was diagnosed as smoldering myeloma based on increased bone marrow plasma cell numbers and monoclonal gammopathy during a regular follow-up visit for JAK2V617F mutation-positive polycythemia vera, which had not been treated except with phlebotomy. This case provides useful clues for understanding the pathogenesis of these two hematological malignancies and the association between them. Here, we report a case of polycythemia vera with a JAK2V617F mutation combined with smoldering myeloma and discuss the clinical significance and pathogenic association between these disorders of different lineages, along with a literature review.
Bone Marrow ; Follow-Up Studies ; Hematologic Neoplasms ; Multiple Myeloma ; Paraproteinemias ; Phlebotomy ; Plasma Cells ; Polycythemia ; Polycythemia Vera

The most common recurrent cytogenetic abnormalities in T-lymphoblastic leukemia (T-acute lymphoblastic leukemia [T-ALL]) involve T-cell receptor (TCR) loci and a variety of partner genes, including HOX11, HOX11L2, MYC, and TAL1. In this report, we present a rare case involving simultaneous translocation of the TCR alpha/delta loci with different partner loci (Xq22 and 12p13); this resulted in a poor prognosis. Chromosomal analysis showed 46,Y,t(X;14)(q22;q11.2),t(12;14)(p13;q11.2) and FISH analysis by using a T-cell receptor alpha delta DNA probe, Split Signal (DakoCytomation, Denmark), showed translocations at the same TCR alpha/delta locus on both chromosomes. FISH with 2 bacterial artificial chromosome clones showed break apart signal, which suggests involvement of the IRS4 gene. To our knowledge, this is the first report of T-ALL in which both TCR alpha/delta loci were translocated with different partner loci, and 1 of the partner loci, Xq22, was a rare translocation partner locus that included IRS4 gene.
Adult ; Chromosomes, Human, Pair 12 ; Chromosomes, Human, Pair 14 ; Chromosomes, Human, X ; Genetic Loci ; Humans ; Insulin Receptor Substrate Proteins/genetics ; Karyotyping ; Male ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*genetics/pathology ; Receptors, Antigen, T-Cell/*genetics ; *Translocation, Genetic